Mission Bio unlocks the ground truth of cancer through response, relapse, and remission with its Tapestri Single-cell Multi-omics Platform. As the only technology to analyze genotype and phenotype simultaneously in single cells, it discerns key biomarkers to stratify patients more precisely, signal treatment resistance as it begins, and predict relapse for better outcomes. Applications include heme-onc, solid tumors, and CGT.
Mission Bio’s Tapestri Platform is the industry’s first and only single-cell multi-omics platform, enabling genotype and phenotype from the same cell and precise detection of heterogeneity underlying disease progression, treatment response, resistance, and relapse. Application areas include blood cancers, solid tumor profiling, and cell and gene therapy. Spun out of research at the University of California, San Francisco, Mission Bio is headquartered in South San Francisco, California.